Guide detail

Ipamorelin and CJC-1295

This protocol outlines the safe and effective use of Ipamorelin and CJC-1295 for advanced users aiming to enhance growth hormone (GH) secretion, muscle growth, and recovery. The combination leverages the synergistic effects of a GHRH analog (CJC-1295) and a GHRP (Ipamorelin) to maximize pulsatile GH release.

  1. Preparation:

    • Ensure all materials are sterile: bacteriostatic water, alcohol swabs, insulin syringes (29-31G), and peptide vials.
    • Reconstitute each peptide with bacteriostatic water per manufacturer guidelines (typically 1-2 mL per vial).
    • Store reconstituted peptides at 2-8°C (refrigerated) and use within 7-10 days.

  2. Dosing:

    • CJC-1295: 100-300 mcg per dose (no DAC version recommended for pulsatile release).
    • Ipamorelin: 100-300 mcg per dose.
    • Administer subcutaneously (abdomen or thigh) at the same time for synergy.

  3. Timing:

    • Dose 1-2 times daily, preferably on an empty stomach (morning and/or post-workout).
    • Avoid food 30 minutes before and after administration to prevent somatostatin interference.

  4. Cycle Length:

    • 8-12 weeks on, followed by 4-8 weeks off to prevent desensitization.
    • Monitor IGF-1 levels pre-, mid-, and post-cycle if possible.

  5. Administration:

    • Rotate injection sites to avoid lipoatrophy.
    • Pinch skin, insert needle at 45-90°, inject slowly, and dispose of sharps safely.

  6. Post-Cycle:

    • Consider a GH secretagogue (e.g., MK-677) during off weeks to maintain benefits.
    • Assess tolerance and adjust future cycles accordingly.
    • Synergy: CJC-1295 amplifies endogenous GH pulses, while Ipamorelin enhances frequency.
    • Timing Matters: Nighttime dosing may improve sleep quality but can disrupt natural GH rhythms.
    • Diet: High-carb meals post-administration may blunt effects; prioritize protein/fat.
    • Stacking: Avoid combining with other GH-secretagogues unless under professional guidance.

Warnings

  • Hypoglycemia Risk: Monitor blood glucose; peptides may enhance insulin sensitivity.
  • Pregnancy/Medical Conditions: Contraindicated in pregnancy, cancer, or active tumors.
  • Side Effects: Report persistent headaches, joint pain, or tingling (may indicate elevated GH/IGF-1).
  • Legal Status: Peptides are research chemicals in many regions; ensure compliance with local laws.
  • Sterility: Never reuse needles or share vials to prevent infections.

References

  • Khorram, O. et al. (2001). 'Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults.' J Clin Endocrinol Metab.
  • Van der Lely, A.J. et al. (2004). 'The role of ghrelin in the regulation of GH secretion.' Endocr Rev.
  • Manufacturer guidelines for CJC-1295 (no DAC) and Ipamorelin.